Mar. 19 2024
Source Page: FOI responses published by MOD: week commencing 18 March 2024Found: homozygous or double heterozygous sickle cell disease, hereditary spherocytosis, homozygous α or β thalassaemia
Mar. 14 2024
Source Page: Q2 (1 July to 30 September 2023) ANNB and YPA screening KPI dataFound: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal
Mar. 14 2024
Source Page: Q1 (1 April to 30 June 2023) ANNB and YPA screening KPI dataFound: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal
Mentions:
1: Bell Ribeiro-Addy (Lab - Streatham) landmark report by the Sickle Cell Society and the all-party parliamentary group on sickle cell and thalassaemia - Speech Link
Asked by: George Howarth (Labour - Knowsley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) NICE and (b) NHS England on encouraging the adoption of new treatments for (i) sickle cell disease and (ii) beta-thalassaemia.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), related to patient access to new treatments.
The NICE appraises all new licensed medicines, and its recommendations are developed independently in line with its established methods and processes, on the basis of an assessment of the available evidence, and through extensive engagement with stakeholders. NHS England is legally required to fund treatments recommended in NICE technology appraisal guidance.
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Foreign, Commonwealth & Development Office:
To ask His Majesty's Government what representations they have made to the government of Pakistan on ensuring the availability of thalassaemia treatment and awareness; and what allocations of the Official Development Aid is being put towards this.
Answered by Lord Ahmad of Wimbledon - Minister of State (Foreign, Commonwealth and Development Office)
The UK uses Official Development Assistance (ODA) to support Pakistan in realising its ambition of Universal Health Coverage (UHC) and ending preventable deaths of mothers, babies and children. We take a systems approach to this, providing technical assistance to strengthen decision making on health policy and financing. We also build the evidence base on effective sub-system interventions for UHC. No specific investments are made in Thalassaemia treatment or awareness raising in Pakistan. However, our support will strengthen core components of Pakistan's health system and increase coverage and service offers that should be of benefit to those with Thalassaemia.
Feb. 06 2024
Source Page: Public Health Outcomes Framework: February 2024 data updateFound: Updated England Region No additional breakdown All ages Yes OHID C24k - Sickle Cell and Thalassaemia
Mentions:
1: Andrew Stephenson (Con - Pendle) Lady in her role as chair of the sickle cell and thalassaemia all-party parliamentary group. - Speech Link
Dec. 14 2023
Source Page: Q1 (1 April to 30 June 2023) ANNB and YPA screening KPI dataFound: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal
Dec. 06 2023
Source Page: FOI responses published by MOD: week commencing 4 December 2023Found: homozygous or double heterozygous sickle cell disease, hereditary spherocytosis, homozygous α or β thalassaemia